Why the study?
Hypertension is associated with endothelial dysfunction, prompting interest in the role of L-arginine, arginine transporters, and ADMA in its pathobiology.
What is the role of L-arginine, arginine transporters, and ADMA in the pathobiology of hypertension?
What is the role of L-arginine, arginine transporters, and ADMA in the pathobiology of hypertension?
This review highlights the importance of the L-arginine/nitric oxide pathway and the inhibitory role of ADMA in the development and pathobiology of hypertension.
Does not support clinical changes in hypertension management; leaves open targeted trials on the L-arginine/ADMA axis.
Hypertension (HTN) is a chronic disease that affects more than 972 million people throughout the world, which is usually associated with endothelial dysfunction. Scientists are closely investigating endothelial dysfunction and have recently discovered the endothelium-derived relaxing factor (EDRF) known as NO (nitric oxide), which is derived from a semi-essential amino acid, L-arginine, by the action of endothelial nitric oxide synthase (eNOS). Production of adequate amounts of NO by vascular endothelial cells is essential to maintain normal blood pressure and prevent the development of HTN. Asymmetrical dimethylarginine (ADMA) is an endogenous NOS inhibitor that is increased in those with HTN especially in patients with renal dysfunction. In the present review, the role of L-arginine, arginine transporters, and ADMA in the pathobiology of HTN and their potential clinical significance are discussed.
No takes yet. Share an insight, caveat, or question.
Abukhodair et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: